PHENIX_revised_supplement_15SEP2021_TRACKED.docx (116.69 kB)
FON-2021-0886 Supplementary Data
dataset
posted on 2021-10-15, 09:54 authored by Oliver Sartor, Daniel George, Bertrand Tombal, Neeraj Agarwal, Celestia S. Higano, Cora N. Sternberg, Kurt Miller, XiaoLong Jiao, Helen Guo, Per Sandström, Amanda Bruno, Frank Verholen, Fred Saad, Neal Shore|
Supplemental Figure 1. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC
Kaplan–Meier curves of time to first SSE after the start of second-line therapy. (A) Radium-223 cohort. (B) Alternative NHT cohort. CI, Confidence interval; NE, Not estimable; NHT, Novel hormonal therapy; SSE, Symptomatic skeletal event. |
